Learn about the program
Find out what the Life Saving Drugs Program is, how it works, which medicines are covered and who can access them.
Apply for LSDP-funded treatment
Find the forms treating physicians need to apply for medicines for their patients under the LSDP.
Our expert panel
See the agenda for the next meeting, how to make a submission, and the outcomes of medicine applications and reviews.
Apply to list a new medicine
Medicine sponsors can read our procedure guidance and template for applying to list a medicine on the LSDP.
Browse the Life Saving Drugs Program for
Patients
Find out how to get medicines through the program and what your responsibilities are.
Treating physicians
See how to start patients on LSDP medicines, comply with program requirements, and make any required changes over time.
Pharmacists
Find out how to become an LSDP pharmacy, manage LSDP medicines correctly, prevent wastage, and keep us informed.
Medicine sponsors
Read the medicines eligibility criteria and find out how to list a medicine on the LSDP.
Soliris® (eculizumab) available on PBS from 1 March 2022
The program that subsidises Soliris® for patients with a rare condition called paroxysmal nocturnal haemoglobinuria (PNH) is changing. Until now, we have subsidised Soliris® under the Life Saving Drugs Program. From 1 March 2022, this will change to the Pharmaceutical Benefits Scheme (PBS).
Latest resources
Latest resources
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations for consumers
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – MPS VI – Review summary and Expert Panel recommendations
This MPS VI review considered galsulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – HT1 – Review summary and Expert Panel recommendations
This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Last updated: